Trial NCT03461952

View at ClinicalTrials.gov 
Org. Study IDs: I235
Secondary IDs: 0001

Last trial update was posted on 2024-02-22

MeSH Interventions

Ipilimumab Nivolumab

MeSH Conditions


Other Conditions

Advanced Solid Tumors

Stopping Reasons

cfDNA screening data found that the prevalence of POLE/POLD1 mutations was lower than expected. It was determined that there are no feasible options to amend this study in a fashion that would not be duplicative of other currently accruing trials.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID